EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Safety of Combined Targeted and Helixor® Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study

Friedemann Schad iD, Anja Thronicke iD

International Journal of Environmental Research and Public Health · 2023

DOI: 10.3390/ijerph20032565 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Friedemann Schad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Network Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany. Hauptthemen laut MEDLINE: Neoplasms, Viscum album. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iscador AG Arlesheim, Switzerland, ABNOBA GmbH Pforzheim, Germany, Astrazeneca GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Newer personalized medicines including targeted therapies such as PARP inhibitors and CDK 4/6 inhibitors have been shown to improve the survival of breast and gynaecological cancer patients. However, efficacy outcomes may be ham5pered by treatment discontinuation due to targeted therapy-related adverse drug reactions or resistance. Studies have suggested that add-on mistletoe (Viscum album L., VA) improves the quality of life and ameliorates the cytotoxic side effects of standard oncological therapy in cancer patients. The primary objective of this real-world data study was to determine the safety profile of targeted therapy in combination with add-on Helixor® VA therapy compared to targeted therapy alone in breast and gynecological cancer patients.

Methods

The present study is a real-world data observational cohort study utilizing demographic and treatment data from the accredited national Network Oncology (NO) registry. The study has received ethics approval. The safety profile of targeted therapies with or without Helixor® VA therapy and safety—associated variables were evaluated by univariate and adjusted multivariable regression analyses.

Results

All stages of breast and gynecological cancer patients (n = 242) were on average 54.5 ± 14.2 years old. One hundred and sixty patients (66.1%) were in the control (CTRL, targeted therapy) and 82 patients (33.9%) were in the combinational (COMB, targeted plus Helixor® VA therapy) group. The addition of Helixor® VA did not hamper the safety profile (χ2 = 0.107, p-value = 0.99) of targeted therapy. Furthermore, no adverse events and a trend towards an improved targeted therapy adherence were observed in the COMB group.

Conclusions

The present study is the first of its kind showing the applicability of Helixor® VA in combination with targeted therapies. The results indicate that add-on Helixor® VA does not negatively alter the safety profile of targeted therapies in breast and gynaecological cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsViscum albumAdultAgedHumansMiddle AgedPlant ExtractsQuality of LifeFemale

Stichwörter der Autor:innen

CDK 4/6 inhibitorsHelixor® VA therapyPARP inhibitorsViscum album L.breast cancerendometrium cancerimmune checkpoint inhibitorsmonoclonal antibody therapyovarian cancersafety analysistargeted therapytyrosine kinase inhibitors

Substanzen

HelixorPlant Extracts

Autor:innen und Institutionen

  • Network Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
  • Oncological Center, Department of Interdisciplinary Oncology and Palliative Care, Hospital Gemeinschaftskrankenhaus Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.

ORCID-Profile: Friedemann Schad, Anja Thronicke

Förderung

  • Iscador AG Arlesheim, Switzerland
  • ABNOBA GmbH Pforzheim, Germany
  • Astrazeneca GmbH
  • Helixor GmbH Rosenfeld, Germany

Zitieren

APA

Schad, F., & Thronicke, A. (2023). Safety of Combined Targeted and Helixor® Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20032565

Vancouver

Schad F, Thronicke A. Safety of Combined Targeted and Helixor® Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20032565

BibTeX
@article{Schad2023,
  author = {Schad, Friedemann and Thronicke, Anja},
  title = {Safety of Combined Targeted and Helixor® Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2023},
  doi = {10.3390/ijerph20032565}
}
Kostenlos starten →